According to filings with the U.S. Securities and Exchange Commission, Myrobalan Therapeutics is raising up to $24,049,258.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jing Wang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Myrobalan Therapeutics
Developing therapeutics to address the unmet need and societal burdens posed by neurodegenerative, demyelinating and neuropsychiatric disorders. Our comprehensive research and development expertise, covering all stages of drug development, is intended to foster coherent decision making. We have confidence in the successful entrepreneurial experience of our founders in building and growing startup biotech companies. Our strategy leverages emerging evidence that points toward shared disease mechanisms such as synaptic dysfunction, neuroinflammation and demyelination. We believe that targeting these shared critical nodes of CNS disorders will increase probability of clinical success and provide therapeutic opportunities for a large patient population with unmet medical needs.

To learn more about Myrobalan Therapeutics, visit http://myrotx.com/

Contact:
Jing Wang, Chief Executive Officer
857-675-1485
https://www.linkedin.com/in/jing-wang-9309751/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.